BioSpace News Archive

Synthekine Inc., an engineered cytokine therapeutics company, today announced a new agreement with Stanford University to license cytokine partial agonist programs for IL-10, IL-12 and IL-22. These programs augment a growing pipeline of selective cytokine partial agonists at Synthekine that is maturing toward clinical development.

Perspectum, a commercial-stage, precision-health company developing proprietary digital technologies that enable clinicians to more accurately diagnose and monitor patients with chronic metabolic diseases, multi-organ pathologies and cancer, announced the appointment of Annalisa Jenkins, MBBS, FRCP to its Board of Directors.

Medtronic Canada ULC, a subsidiary of Medtronic plc (NYSE: MDT) — the world’s largest medical technology, services, and solutions company — has been named on the 2021 list of Canada’s Greenest Employers.

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a 39-cent second-quarter 2021 dividend on the company’s common stock, payable June 4, 2021, to holders of the Common Stock of record at the close of business on May 7, 2021.

Cigna is introducing a broad range of new initiatives to encourage and expand access to COVID-19 vaccinations.

Designed for TLIF procedures, the 3D-printed FORZA Ti Spacer System further expands the comprehensive line of PEEK, PTC, and now Titanium interbody solutions offered by Orthofix for transforaminal lumbar applications

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, announces lumateperone presentations at the upcoming American Psychiatric Association (APA) Annual Meeting to be held May 1-3, 2021 and will hold a webcast on May 4, 2021.

Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and leukotriene systems are implicated, announced today that it will present a poster at the American Academy of Dermatology Association (AAD) Virtual Meeting Experience (VMX) taking place April 23-25, 2021.

MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, today announced it has enrolled the first patient in its phase 2 pharmacology study of EscharEx®,

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System , the first drug-eluting coronary artery implant that adapts to vessel physiology.